Neoadjuvant PD-1 blockade with toripalimab with or without celecoxib for patients with mismatch repair-deficient or microsatellite instability-high, locally advanced, colorectal cancer (PICC): long-term outcomes of a single-centre, parallel-group, non-comparative, randomised phase 2 trial.

ABSTRACT:

Background

Neoadjuvant PD-1 blockade has demonstrated high rates of pathological complete response in patients with mismatch repair-deficient or microsatellite instability-high, locally advanced colorectal cancer. However, prospective data on long-term survival remain limited. Here, we report the 5-year outcomes from the phase 2 PICC study (NCT03926338) evaluating neoadjuvant toripalimab with or without celecoxib in this population.

Methods

The PICC study was a single-centre, open-label, parallel-group, non-comparative, randomised, phase 2 study. A total of 34 patients with stage II-III mismatch repair-deficient or microsatellite instability-high colorectal cancer were enrolled between May 1, 2019, and April 1, 2021, and randomly assigned (1:1) to receive neoadjuvant toripal

SUBMITTER: Shen X 

PROVIDER: S-EPMC12572784 | biostudies-literature | 2025 Oct

REPOSITORIES: biostudies-literature